BI 207127 + omeprazole

BI 207127 (deleobuvir) is a highly potent and specific non-nucleoside inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. It acts by binding to pocket 1 of the thumb domain of NS5B and inhibits viral replication. Omeprazole is a proton pump inhibitor that decreases gastric acid production by irreversibly inhibiting the H+/K+ ATPase enzyme in gastric parietal cells. Omeprazole is widely used for conditions such as gastroesophageal reflux disease (GERD), peptic ulcer disease, Zollinger-Ellison syndrome, and for eradication of Helicobacter pylori infection when combined with antibiotics. BI 207127 was developed primarily for HCV genotype-1 infection but its development was discontinued due to suboptimal efficacy against genotype-1a. The combination "BI 207127 + omeprazole" does not represent a standard fixed-dose pharmaceutical product but rather refers to co-administration or study use.

Brand names

PrilosecLosecZegeridOmeclamoxOmesecKonvomepPrevidolrx Analgesic PakTaliciaYosprala

Other names

deleobuvir